Video

TKIs in Philadelphia Chromosome-Positive ALL

For High-Definition, Click

The introduction of tyrosine kinase inhibitors (TKIs), like imatinib, for Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia (ALL) has revolutionized outcomes in younger patients and created an opportunity for more definitive therapy in older individuals, according to Jeffrey Lancet, MD. Lancet notes that several smaller series of studies have demonstrated high response rates and significant disease-free survival rates in individuals who received TKIs with modified chemotherapeutic regimens or steroids.

Dan Douer, MD, and Mark R. Litzow, MD, agree that adults with Ph+ ALL should undergo allogeneic stem cell transplant following treatment with TKIs. In many instances, the level of response induced by targeted therapies lends itself to better outcomes from transplant. However, whether imatinib should be administered following transplantation remains an area of debate.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Latest CME

View All
(CME Track) Clinical Consultations™: Framing a New Approach to Geographic Atrophy Management – Expert Insights into Recent Developments
Video

(CME Track) Clinical Consultations™: Framing a New Approach to Geographic Atrophy Management – Expert Insights into Recent Developments

Apr 23rd 2025 - Apr 24th 2026

online-activity
Optimizing Today and Looking to Tomorrow in Metastatic CRPC—Homing in on EZH2
Video

Optimizing Today and Looking to Tomorrow in Metastatic CRPC—Homing in on EZH2

Apr 23rd 2025 - Apr 24th 2026

online-activity
Addressing Unmet Needs in HER2+ Metastatic BTC
Video

Addressing Unmet Needs in HER2+ Metastatic BTC

Apr 18th 2025 - Apr 19th 2026

online-activity